ArticleGastroenterology report2024
Tumor regression pattern may impact the prognosis of rectal cancer patients with tumor regression grade 1 after neoadjuvant chemoradiotherapy.
Article in Gastroenterology report, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Synergistic effects of sacituzumab govitecan and radiotherapy in preclinical models of colorectal cancer.Gastroenterology report · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tumor regression grade (TRG) is evaluated by calculating the proportion of residual tumor to stromal fibrosis, which can reflect the tumor response to neoadjuvant chemoradiotherapy (NCRT) in patients with locally advanced rectal cancer (LARC). Overall, patients with TRG1 show good sensitivity to NCRT but the long-term survival for these patients remains different. This study aimed to assess the prognostic factors in patients with TRG1. Methods: LARC patients who underwent NCRT and radical surgery were included. TRG was evaluated according to the National Comprehensive Cancer Network guidelines. The association between clinicopathological factors and survival outcomes was assessed in patients with TRG1. Overall survival (OS) and disease-free survival (DFS) were evaluated using both Kaplan-Meier analyses and Cox proportional hazards models. Results: Of the 393 LARC patients, 104 (26.5%) were diagnosed with TRG1. The 5-year OS rates and 5-year DFS rates of patients with TRG1 were 90.9% and 72.2%, respectively. In patients with TRG1, the tumor regression pattern ( Conclusions: TRG could be a prognostic variable for LARC patients receiving NCRT. In patients with TRG1, the tumor regression pattern may represent another useful prognostic factor to better individualize the prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.